Clinical Trial

Pharmacokinetics (PK) and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment (HI)

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated June 22, 2025 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
The primary purpose of this study is to evaluate the plasma PK of zanzalintinib following a single dose in participants with moderate liver dysfunction compared to matched healthy participants with normal liver function.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-04-30.
Status change: Not Yet Recruiting → Recruiting 2025-06-17
Trial Details
NCT Number NCT06962332
Lead Sponsor Exelixis
Conditions Hepatic Impairment, Moderate Hepatic Impairment
Enrollment 20 participants
Start Date 2025-05-13
Primary Completion 2025-12 (estimated)
Study Completion 2026-04 (estimated)
Updated on ClinicalTrials.gov 2025-06-22